Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pineamin is a peptide bioregulator developed by the Saint Petersburg Institute of Bioregulation and Gerontology in collaboration with Geropharm. It consists of a complex of water-soluble polypeptide fractions (PPG class) extracted from the pineal gland (epiphysis) of young animals. The drug's primary mechanism of action involves stimulating melatonin synthesis and restoring the melatonin-forming function of the pineal gland, which typically declines with age. Pineamin is formulated as a lyophilisate for intramuscular injection and is indicated for aging-related conditions, sleep disorders, endocrine disorders, and climacteric syndrome in women. Clinical studies have shown that it significantly increases the urinary excretion of 6-sulfatoxymelatonin, a metabolite of melatonin, in elderly patients, indicating improved pineal function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pineamin.